2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1767

Poor Body Image in Lupus: Is It Disease Activity, Damage, Sleep, Pain, Fatigue, Stress, Function, Medications, Depression or Fibromyalgia?
Abstract Number: 1768

Fatigue in SLE Is Associated with Neuropsychiatric Involvement, Pain, Impaired Sleep and a Reduced Quality of Life
Abstract Number: 1769

Fatigue in Anti-Nuclear Antibody Positive Individuals with Insufficient Criteria to Diagnose a Systemic Autoimmune Rheumatic Disease
Abstract Number: 1770

The Impact of Comorbidities on Quality of Life in Systemic Lupus Erythematosus in the First 10 Years
Abstract Number: 1771

Depression Is Associated with a Poorer with Health-Related Quality of Life in Patients with Systemic Lupus Erythematosus
Abstract Number: 1772

WITHDRAWN
Abstract Number: 1773

Risk Factors for Cerebrovascular Events in Systemic Lupus Erythematosus: Results from an International, Inception Cohort Study
Abstract Number: 1774

Chronological Analysis of Damage Accrual in Patientes with Systemic Lupus Erythematosus: Results from the Spanish Registry of Patients with SLE of the Spanish Society of Rheumatology (RELESSER)
Abstract Number: 1775

Smoking As a Predictor of Cutaneous Activity in Systemic Lupus Erythematosus
Abstract Number: 1776

Analysis of Progressive Brain and Corpus Callosum Atrophy and Association with Th1 and Th2 Cytokines in Systemic Lupus Erythematosus
Abstract Number: 1777

The Accumulation of Organ Damage, Public Insurance Enrollment and Youth Are Associated with Increased Hospitalizations in a Population-Based Cohort of Lupus Patient
Abstract Number: 1778

Differences Between Early and Late Cardiovascular Disease in a Population-Based Cohort of Systemic Lupus Erythematosus Patients
Abstract Number: 1779

Remission and Low Lupus Disease Activity Status (LLDAS) Protect Lupus Patients from Damage Occurrence: Data from a Multi-Ethnic, Multinational Latin American Lupus Cohort
Abstract Number: 1780

Pulmonary Disease in Late Versus Early Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Abstract Number: 1781

Analysis of Influences of Various Factors on the Prognosis of Acute Confusional State of Diffuse Psychiatric/Neuropsychological Syndromes in Systemic Lupus Erythematosus

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].